These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 17577009)

  • 21. Successful use of adalimumab (Humira) for Crohn's disease in pregnancy.
    Mishkin DS; Van Deinse W; Becker JM; Farraye FA
    Inflamm Bowel Dis; 2006 Aug; 12(8):827-8. PubMed ID: 16917239
    [No Abstract]   [Full Text] [Related]  

  • 22. Adalimumab: in Crohn's disease.
    Plosker GL; Lyseng-Williamson KA
    BioDrugs; 2007; 21(2):125-32; discussion 133-4. PubMed ID: 17402796
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Should patients under long-term anti-TNF therapies be followed for tuberculosis contamination?
    Reenaers C; Belaiche J; Louis E
    Inflamm Bowel Dis; 2010 Aug; 16(8):1271-2. PubMed ID: 20027649
    [No Abstract]   [Full Text] [Related]  

  • 24. Safety and efficacy of adalimumab in pediatric patients with Crohn disease.
    Wyneski MJ; Green A; Kay M; Wyllie R; Mahajan L
    J Pediatr Gastroenterol Nutr; 2008 Jul; 47(1):19-25. PubMed ID: 18607264
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Managing Crohn disease in children and adolescents : focus on tumor necrosis factor antagonists.
    Saeed SA; Crandall WV
    Paediatr Drugs; 2008; 10(1):31-8. PubMed ID: 18162006
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Severe anaphylactic reaction to infliximab: successful treatment with adalimumab - report of a case.
    Stallmach A; Giese T; Schmidt C; Meuer SC; Zeuzem SS
    Eur J Gastroenterol Hepatol; 2004 Jun; 16(6):627-30. PubMed ID: 15167167
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Infliximab and adalimumab-induced psoriasis in Crohn's disease: a paradoxical side effect.
    Iborra M; Beltrán B; Bastida G; Aguas M; Nos P
    J Crohns Colitis; 2011 Apr; 5(2):157-61. PubMed ID: 21453886
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New pancreatic adenocarcinoma in a Crohn's patient treated with tumor necrosis factor (TNF) inhibitors for 6 months.
    Patel R; Lara S; Johnson J; Kulkarni P
    J Gastrointest Cancer; 2014 Dec; 45 Suppl 1():226-9. PubMed ID: 25027498
    [No Abstract]   [Full Text] [Related]  

  • 29. Update on anti-tumor necrosis factor agents in Crohn disease.
    Singh S; Pardi DS
    Gastroenterol Clin North Am; 2014 Sep; 43(3):457-78. PubMed ID: 25110253
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A retrospective comparison of infliximab versus adalimumab as induction and maintenance therapy for Crohn disease.
    Varma P; Paul E; Huang C; Headon B; Sparrow MP
    Intern Med J; 2016 Jul; 46(7):798-804. PubMed ID: 26865349
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Crohn's disease - treatment with biological medication.
    Zaltman C; Amarante H; Brenner MM; Costa MHM; Flores C; Leal RF; Grain JFS; Zeroncio M
    Rev Assoc Med Bras (1992); 2019 May; 65(4):554-567. PubMed ID: 31066809
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adalimumab, a novel anti-tumor necrosis factor-alpha antibody in a child with refractory Crohn's disease.
    Mian S; Baron H
    J Pediatr Gastroenterol Nutr; 2005 Sep; 41(3):357-9. PubMed ID: 16131995
    [No Abstract]   [Full Text] [Related]  

  • 33. Basophil activation test in a case of systemic hypersensitivity reaction to infliximab with good tolerance to another anti-TNF-alpha agent (adalimumab).
    Manso L; Polo B; Fernández-Nieto M; Sastre LB; del Pozo V; Sastre J
    J Investig Allergol Clin Immunol; 2010; 20(6):537-8. PubMed ID: 21243942
    [No Abstract]   [Full Text] [Related]  

  • 34. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
    Magro F; Portela F
    BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Crohn's disease--infliximab, adalimumab and certolizumab-pegol: clinical value of anti-TNF-alpha treatment].
    Schreiber S
    Dtsch Med Wochenschr; 2007 Aug; 132(34-35):1770-4. PubMed ID: 17713889
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Elective switching from infliximab to adalimumab in stable Crohn's disease.
    Hoentjen F; Haarhuis BJ; Drenth JP; de Jong DJ
    Inflamm Bowel Dis; 2013; 19(4):761-6. PubMed ID: 23446337
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy of adalimumab for the management of inflammatory bowel disease in the clinical setting.
    Trinder MW; Lawrance IC
    J Gastroenterol Hepatol; 2009 Jul; 24(7):1252-7. PubMed ID: 19220669
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term MRI-guided combined anti-TNF-α and thiopurine therapy for Crohn's perianal fistulas.
    Tozer P; Ng SC; Siddiqui MR; Plamondon S; Burling D; Gupta A; Swatton A; Tripoli S; Vaizey CJ; Kamm MA; Phillips R; Hart A
    Inflamm Bowel Dis; 2012 Oct; 18(10):1825-34. PubMed ID: 22223472
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Main therapeutic advances in IBD in 2007].
    Felley C; Mottet C; Maillard MH; Hess J; Delarive J; Michetti P
    Rev Med Suisse; 2008 Jan; 4(141):200, 202-4, 206-8 passim. PubMed ID: 18335885
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety and efficacy of adalimumab (D2E7) in Crohn's disease patients with an attenuated response to infliximab.
    Papadakis KA; Shaye OA; Vasiliauskas EA; Ippoliti A; Dubinsky MC; Birt J; Paavola J; Lee SK; Price J; Targan SR; Abreu MT
    Am J Gastroenterol; 2005 Jan; 100(1):75-9. PubMed ID: 15654784
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.